With this rationale, we conducted a single-arm phase 2 trial to investigate the safety and efficacy of venetoclax combined with chidamide, azacitidine, cytarabine, aclarubicin, and G-CSF as an induction treatment (referred to as CACAG-VEN) for older adults (aged ≥ 60 years) with newly diagnosed AML. The gene discussed is CSF3; the disease is acute myeloid leukemia.